April 23, 2019
Neurogene Initiates Natural History Study of Aspartylglucosaminuria (AGU)
Neurogene Initiates Natural History Study of Aspartylglucosaminuria (AGU)
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
April 22, 2019
Lilly’s drug Taltz for nr-axSpA meets endpoints in Phase 3 testing, approval application expected this year
Eli lilly is encouraged by the results of the COAST-X trial, which support its belief that Taltz could become the first IL-17A antagonist to be approved in the U.S. for people with non-radiographic axSpA, said Christi Shaw, president, Lilly Bio-Medicines.
April 22, 2019
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
Pfizer and Eli lilly have announced top-line results from a Phase 3 study evaluating tanezumab 2.5mg and 5 mg.
April 22, 2019
Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development
Veracyte has named Alfred “Freddie” Bowie, Jr., Ph.D., as vicepresident, corporate and business development.
April 22, 2019
Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
Teva has launched generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
April 22, 2019
Rising Pharma Holdings, Inc. Completes Purchase of Rising Pharmaceuticals, Inc.
Rising Pharma Holdings has completed the purchase of the assets of RisingPharmaceuticals and Rising’s subsidiaries on a cash-free and debt-freebasis.
April 22, 2019
GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
Preclinical studies indicatethat targeting both E-selectin and CXCR4 with a single compound couldimprove efficacy in the treatment of cancers that involve the bonemarrow such as AML and multiple myeloma or in solid tumors thatmetastasize to the bone, such as prostate cancer and breast cancer.
April 22, 2019
Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials
Novus said the results from single-dose phase 1 studies met theprimary objectives and demonstrated a favorable safety and tolerabilityprofile
April 22, 2019
Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
Aura Biosciences’ lead productcandidate for the primary treatment of primary choroidal melanoma, willbe highlighted in a poster presentation at the Association for Researchin Vision and Ophthalmology (ARVO) 2019 Annual Meeting
April 22, 2019
CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)
BELRAPZO is indicated for the treatment of patients with indolent B-cellnon-Hodgkin lymphoma (NHL) that has progressed during or within sixmonths of treatment with rituximab or a rituximab-containing regimen.